Ovid Therapeutics to Present at the Oppenheimer 35th Annual Healthcare Life Sciences Conference
NEW YORK, Feb. 05, 2025 (GLOBE NEWSWIRE) -- Ovid Therapeutics Inc. (Nasdaq: OVID), a biopharmaceutical company dedicated to developing medicines...
Month: February 2025
Annovis Announces First Patients Entered into Pivotal Phase 3 Study of Buntanetap for Early Alzheimer’s Disease
MALVERN, Pa., Feb. 05, 2025 (GLOBE NEWSWIRE) -- via IBN – Annovis Bio Inc. (NYSE: ANVS) ("Annovis" or the "Company"),...
Indaptus Therapeutics Receives Approval from Health Canada to Expand Clinical Trial of Decoy20
NEW YORK, Feb. 05, 2025 (GLOBE NEWSWIRE) -- Indaptus Therapeutics, Inc. (Nasdaq: INDP) (“Indaptus” or the “Company”), a clinical-stage biotechnology...
Akoya Biosciences Unveils Strategic Product Roadmap, Powered by the New IO60 and Upcoming Neurobiology Panels
Rapid menu expansion with new high-plex human and mouse neurobiology panels joining the recently launched Human IO60 and Mouse FFPE...
Vaxcyte Advances to Second Stage of Ongoing Phase 2 Study Evaluating VAX-31 for the Prevention of Invasive Pneumococcal Disease in Infants
-- Advancement to Stage 2 of Infant Study Supported by Review of Stage 1 Safety and Tolerability Data -- --...
Aprea Therapeutics Announces Strategic IP Portfolio Evolution in DNA Damage Response (DDR) Cancer Therapeutics
DOYLESTOWN, Pa., Feb. 05, 2025 (GLOBE NEWSWIRE) -- Aprea Therapeutics, Inc. (Nasdaq: APRE) (“Aprea”, or the “Company”), a clinical-stage biopharmaceutical company...
Ventyx Biosciences to Participate in the Oppenheimer 35th Annual Healthcare Life Sciences Conference
SAN DIEGO, Feb. 05, 2025 (GLOBE NEWSWIRE) -- Ventyx Biosciences, Inc. (Nasdaq: VTYX) (“Ventyx”, “Company”), a clinical-stage biopharmaceutical company focused...
e-therapeutics to Present Preclinical Data on ETX-148 at EAHAD 2025
LONDON, Feb. 05, 2025 (GLOBE NEWSWIRE) -- e-therapeutics plc, a company integrating computational power and biological data to discover life-transforming...
Rhythm Pharmaceuticals to Present at Oppenheimer Annual Healthcare Life Sciences Conference in February
BOSTON, Feb. 05, 2025 (GLOBE NEWSWIRE) -- Rhythm Pharmaceuticals, Inc. (Nasdaq: RYTM), a commercial-stage biopharmaceutical company focused on transforming the...
Lifeward Finalizes Personal Exoskeleton Reimbursement Agreement with BARMER, Adding 8.5 Million Covered Lives in Germany
Lifeward signs contractual agreement with BARMER, Germany’s second largest statutory health insurance company, to streamline access to ReWalk Personal Exoskeletons...
Nextech Wins Two Best in KLAS Awards, Earning Top Honors in Dermatology and Ophthalmology
Recognized for the second consecutive year, Nextech secures Best in KLAS for Ambulatory Specialty EHR and celebrates its first-time win...
E-Star BioTech Announces Dosing of First Patient in Phase 2 Clinical Trials of MANP in Resistant Hypertension
NEW YORK, Feb. 05, 2025 (GLOBE NEWSWIRE) -- E-Star BioTech, LLC (“E-Star” or the “Company”), an innovative developer of novel peptides...
Protara Therapeutics to Present at the Oppenheimer 35th Annual Healthcare Life Sciences Conference
NEW YORK, Feb. 05, 2025 (GLOBE NEWSWIRE) -- Protara Therapeutics, Inc. (Nasdaq: TARA), a clinical-stage company developing transformative therapies for the...
PDS Biotech Reaffirms Guidance for First Quarter Initiation of VERSATILE-003 Phase 3 Clinical Trial in HPV16-Positive Recurrent/Metastatic Head and Neck Squamous Cell Carcinoma
FDA-cleared amended trial design; First site initiation expected Q1 2025PRINCETON, N.J., Feb. 05, 2025 (GLOBE NEWSWIRE) -- PDS Biotechnology Corporation...
Erasmus Medical Center Safety Committee Grants Approval to Proceed with Phase 2 Study of Ampligen® and Imfinzi as a Potential Combination Therapy for Late-Stage Pancreatic Cancer
Safety Committee approval based on positive Phase 1 safety data demonstrating the combination therapy to be generally well-tolerated with no...
R1 Wins ‘Best in KLAS’ Across Multiple RCM Categories for 2025
Customers Say R1’s Focus on Delivering Innovation & Expertise is Solving Healthcare ChallengesMURRAY, Utah, Feb. 05, 2025 (GLOBE NEWSWIRE) --...
Health Catalyst to Announce Fourth Quarter and Full Year 2024 Operating Results and Host Conference Call on Wednesday, February 26, 2025
SALT LAKE CITY, Feb. 05, 2025 (GLOBE NEWSWIRE) -- Health Catalyst, Inc. ("Health Catalyst", Nasdaq: HCAT), a leading provider of...
MIMEDX to Host Fourth Quarter and Full Year 2024 Operating and Financial Results Conference Call on February 26
MARIETTA, Ga., Feb. 05, 2025 (GLOBE NEWSWIRE) -- MiMedx Group, Inc. (Nasdaq: MDXG) (“MIMEDX” or the “Company”) today announced that...
ARS Pharmaceuticals to Participate in the Oppenheimer 35th Annual Healthcare Conference
SAN DIEGO, Feb. 05, 2025 (GLOBE NEWSWIRE) -- ARS Pharmaceuticals, Inc. (Nasdaq: SPRY), a biopharmaceutical company dedicated to empowering at-risk...
Collegium Appoints Nancy S. Lurker to its Board of Directors
STOUGHTON, Mass., Feb. 05, 2025 (GLOBE NEWSWIRE) -- Collegium Pharmaceutical, Inc. (Nasdaq: COLL) today announced the appointment of Nancy S....